GW-501516 vs Retatrutide for weight loss
Short answer: For weight loss, more users report improvement with Retatrutide — 91% of 221 reports, versus 86% of 50 for GW-501516.
GW-501516 has 0 meta-analyses and 0 randomized trials on PubMed; Retatrutide has 22 and 6.
Based on 307 reports about GW-501516 and 440 about Retatrutide. Not medical advice.
| GW-501516 Substance | Retatrutide Peptide | |
|---|---|---|
| User score | 46 | 71 |
| Verdict | Mostly positive | Mostly positive |
| Positive of reports that state an outcome | 64% | 76% |
| Reports | 307 | 440 |
| Research | DResearch: None | BResearch: Moderate |
| Meta-analyses / RCTs | 0 / 0 | 22 / 6 |
| Mainly used for | ||
| Weight loss % reporting improvement | 86% (50) | 91% (221) |
| Appetite % reporting improvement | 50% (4) | 72% (82) |
| Focus % reporting improvement | — | 83% (6) |
| Energy % reporting improvement | 95% (19) | 69% (74) |
| Sleep % reporting improvement | 0% (2) | 31% (26) |
| Anxiety % reporting improvement | — | 40% (5) |
| Mood % reporting improvement | 100% (2) | 65% (31) |
| Performance % reporting improvement | 93% (71) | 81% (31) |
| Recovery % reporting improvement | 100% (3) | 100% (8) |
| Pain & inflammation % reporting improvement | — | 78% (9) |
| Digestion % reporting improvement | — | 42% (12) |
| Libido % reporting improvement | — | 25% (12) |
| Hormones % reporting improvement | — | 100% (13) |
| Blood sugar % reporting improvement | — | 75% (4) |
| Heart & lipids % reporting improvement | 89% (19) | 37% (19) |
| Longevity % reporting improvement | 50% (2) | — |
| Common side effects | cancer risk, acne, fatigue, brain fog | nausea, fatigue, stomach issues, insomnia |
| Typical dose reported | 20 mg | Not listed |
This systematic review identifies the state and mechanism of action of emerging pharmacotherapies undergoing or having completed phase 2 and phase 3 clinical trials. The information provided herein furthers the understanding of obesity management, implying direct clinical implications and stimulating research initiatives.
Pharmacol Rev, 2025 ↗“Same with my friend who has been trying Retatrutide from the same vendor.”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate